


Ask a doctor about a prescription for OLMESARTAN/AMLODIPINE CINFA 20 mg/5 mg FILM-COATED TABLETS
Package Leaflet: Information for the User
Olmesartan/Amlodipine Cinfa 20 mg/5 mg Film-Coated Tablets EFG
Olmesartan Medoxomil/Amlodipine
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the Package Leaflet
Olmesartan/Amlodipine Cinfa contains two active substances called olmesartan medoxomil and amlodipine (as amlodipine besylate). Both substances help control high blood pressure.
The action of both substances contributes to preventing the narrowing of blood vessels, so they relax and blood pressure decreases.
This medication is used to treat high blood pressure in patients whose blood pressure is not adequately controlled with olmesartan medoxomil or amlodipine alone.
Do not take Olmesartan/Amlodipine Cinfa
Warnings and Precautions
Consult your doctor or pharmacist before starting to take Olmesartan/Amlodipine Cinfa.
Tell your doctorif you are taking any of the following medications used to treat high blood pressure (hypertension):
Your doctor may need to monitor your kidney function, blood pressure, and blood electrolyte levels (e.g., potassium) at regular intervals.
See also the information under the heading "Do not take Olmesartan/Amlodipine Cinfa".
Tell your doctorif you have any of the following health problems:
Consult your doctor if you experience abdominal pain, nausea, vomiting, or diarrhea after taking Olmesartan/Amlodipine. Your doctor will decide whether to continue treatment. Do not stop taking Olmesartan/Amlodipine on your own.
Contact your doctor if you experience severe, persistent diarrhea that causes significant weight loss. Your doctor will assess your symptoms and decide how to proceed with your blood pressure treatment.
As with any other medication that lowers blood pressure, an excessive decrease in blood pressure in patients with altered blood flow to the heart or brain may cause a heart attack or stroke. Therefore, your doctor will carefully monitor your blood pressure.
You must inform your doctor if you are pregnant or think you may be pregnant. Olmesartan medoxomil/amlodipine is not recommended at the start of pregnancy, and it should not be taken if you are pregnant for more than 3 months, as it may cause serious harm to your baby if taken at this stage (see section "Pregnancy and Breastfeeding").
Children and Adolescents (Under 18 Years)
This medication is not recommended for children and adolescents under 18 years.
Taking Olmesartan/Amlodipine Cinfa with Other Medications
Inform your doctor or pharmacist if you are taking, have recently taken, or may take any other medication.
Your doctor may need to adjust your dose and/or take other precautions:
If you are taking an angiotensin-converting enzyme inhibitor (ACE inhibitor) or aliskiren (see also the information under the headings "Do not take Olmesartan/Amlodipine Cinfa" and "Warnings and Precautions").
Taking Olmesartan/Amlodipine Cinfa with Food and Drinks
Olmesartan medoxomil/amlodipine can be taken with or without food. Take the tablets with a little liquid (such as a glass of water). If possible, take your daily dose at the same time each day, for example, at breakfast time.
People taking Olmesartan medoxomil/amlodipine should not consume grapefruit or grapefruit juice. This is because grapefruit and grapefruit juice can lead to an increase in the levels of the active ingredient amlodipine in the blood, which may cause an unpredictable increase in the blood pressure-lowering effect of this medication.
Elderly Patients
If you are over 65 years old, your doctor will regularly monitor your blood pressure each time your dose is increased, to ensure that it does not decrease too much.
Black Patients
As with other similar medications, the blood pressure-lowering effect of Olmesartan medoxomil/amlodipine is somewhat smaller in black patients.
Pregnancy and Breastfeeding
Pregnancy
You must inform your doctor if you are pregnant or think you may be pregnant.
Your doctor will advise you to stop taking Olmesartan medoxomil/amlodipine before becoming pregnant or as soon as you know you are pregnant, and will advise you to take another medication instead of Olmesartan medoxomil/amlodipine. It is not recommended to use this medication at the start of pregnancy, and it should not be taken if you are pregnant for more than 3 months, as it may cause serious harm to your baby if taken at this stage.
If you become pregnant while taking Olmesartan medoxomil/amlodipine, inform your doctor immediately.
Breastfeeding
Inform your doctor if you are breastfeeding or about to start breastfeeding. It has been shown that amlodipine passes into breast milk in small amounts. This medication is not recommended for breastfeeding mothers, and your doctor may choose another treatment if you wish to breastfeed, especially if your baby is newborn or premature.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Driving and Using Machines
During treatment for high blood pressure, you may feel drowsy, feel sick, or have headaches. If this happens, do not drive or use machines until the symptoms have disappeared. Consult your doctor.
Olmesartan/Amlodipine Cinfa contains sodium.
This medication contains less than 23 mg of sodium (1 mmol) per tablet; this is, essentially "sodium-free".
Follow the instructions for administration of this medication exactly as indicated by your doctor or pharmacist. If you are unsure, consult your doctor or pharmacist again.
If you take more Olmesartan/Amlodipine Cinfa than you should
If you take more tablets than you should, you will probably experience a drop in blood pressure, accompanied by symptoms such as dizziness, and rapid or slow heart rate.
If you take more tablets than you should, or a child accidentally ingests some tablets, contact your doctor or go to the nearest emergency center immediately and bring the medication package or this package leaflet with you.
Excess fluid may accumulate in the lungs (pulmonary edema) causing difficulty breathing, which can develop up to 24-48 hours after ingestion.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, telephone 91 562 04 20, indicating the medication and the amount ingested.
If you forget to take Olmesartan/Amlodipine Cinfa
If you forget to take a dose, take your usual dose the next day. Do not take a double dose to make up for forgotten doses.
If you stop taking Olmesartan/Amlodipine Cinfa
It is important to continue taking Olmesartan medoxomil/amlodipine, unless your doctor tells you to stop treatment.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them. If they occur, they are often mild and do not require interruption of treatment.
The following adverse effects may be serious, although they affect only a small group of people:
During treatment with olmesartan medoxomil/amlodipine, allergic reactions can occur, which can affect the whole body, with inflammation of the face, mouth and/or larynx (vocal cords), along with itching and skin rash. Severe skin reactions including intense skin rash, hives, redness of the skin all over the body, intense itching, blistering, peeling, and skin inflammation, inflammation of the mucous membranes (Stevens-Johnson syndrome, toxic epidermal necrolysis) or other allergic reactions. If this happens to you, stop taking olmesartan medoxomil/amlodipine and consult your doctor immediately.
This medicine may cause a pronounced drop in blood pressure, in susceptible patients, or as a result of an allergic reaction. This can cause fainting or severe dizziness. If this happens to you, stop taking olmesartan medoxomil/amlodipine, consult your doctor immediately, and remain lying down in a horizontal position.
Unknown frequency: If you experience yellowing of the whites of the eyes, dark urine, itching of the skin, even if you started treatment with olmesartan medoxomil/amlodipine a long time ago, contact your doctor immediatelywho will evaluate your symptoms and decide how to continue with blood pressure treatment.
Other possible adverse effects with olmesartan medoxomil/amlodipine:
Frequent (may affect up to 1 in 10 people):
Dizziness; headache; swelling of the ankles, feet, legs, hands, or arms; fatigue.
Uncommon (may affect up to 1 in 100 people):
Dizziness when standing up; lack of energy; tingling or numbness of the hands or feet; vertigo; noticing heartbeats; rapid heartbeat; low blood pressure with symptoms such as dizziness, dizziness; difficulty breathing; cough; nausea; vomiting; indigestion; diarrhea; constipation; dry mouth; pain in the upper abdomen; skin rash; cramps; pain in arms and legs; back pain; feeling of urgency to urinate; sexual inactivity; inability to have or maintain an erection; weakness.
Some changes in the results of certain blood tests have also been observed: increase, as well as decrease in blood potassium levels, increase in blood creatinine levels, increase in uric acid levels, increase in liver function test values (gamma glutamyl transferase levels).
Rare (may affect up to 1 in 1,000 people):
Hypersensitivity to the medicine; fainting; redness and feeling of heat in the face; red itchy hives (urticaria); facial inflammation.
Adverse effects reported with the use of olmesartan medoxomil or amlodipine alone, but not with olmesartan medoxomil/amlodipine, or with a higher frequency:
Olmesartan medoxomil
Frequent (may affect up to 1 in 10 people):
Bronchitis; sore throat; nasal congestion and secretion; cough; abdominal pain; viral gastroenteritis; diarrhea; indigestion; nausea; joint and bone pain; back pain; blood in the urine; urinary tract infection; chest pain; flu-like symptoms; pain. Changes in blood test results, such as increased levels of a type of fat (hypertriglyceridemia); increased uric acid and urea in the blood and increased liver and muscle function test values.
Uncommon (may affect up to 1 in 100 people):
Decrease in the number of a type of blood cells called platelets, which can cause easy bruising or prolonged bleeding time; rapid allergic reactions, which can affect the whole body and cause respiratory problems, as well as a rapid drop in blood pressure, which can even cause fainting (anaphylactic reactions); angina (chest pain or discomfort known as angina pectoris); itching; skin rash; allergic skin rash; urticaria rash; facial swelling; muscle pain; discomfort.
Rare (may affect up to 1 in 1,000 people):
Inflammation of the face, mouth, and/or larynx (vocal cords); acute kidney failure and kidney failure; lethargy.
Intestinal angioedema: swelling in the intestine that presents symptoms such as abdominal pain, nausea, vomiting, and diarrhea.
Amlodipine
Very frequent (may affect more than 1 in 10 people):
Edema (fluid retention).
Frequent (may affect up to 1 in 10 people):
Abdominal pain; nausea; swelling of the ankles; feeling of sleep; redness and feeling of heat in the face, visual disturbances (including double vision and blurred vision), noticing heartbeats, diarrhea, constipation, indigestion, cramps, weakness, difficulty breathing.
Uncommon (may affect up to 1 in 100 people):
Difficulty sleeping; sleep disorders; mood changes including anxiety; depression; irritability; tremors; taste disturbances; fainting; ringing in the ears (tinnitus); worsening of angina pectoris (chest pain or discomfort); irregular heartbeat; nasal secretion or congestion; hair loss; purple spots or spots on the skin due to small hemorrhages (purpura); skin discoloration; excessive sweating; skin rash; itching; red itchy hives (urticaria); joint or muscle pain; urination problems; need to urinate at night; increased need to urinate, increased breast size in men, chest pain; pain; feeling of discomfort; weight gain or loss.
Rare (may affect up to 1 in 1,000 people):
Confusion.
Very rare (may affect up to 1 in 10,000 people):
Decrease in the number of white blood cells, which could increase the risk of infections; decrease in the number of a type of blood cells called platelets, which could lead to bruising and prolonged bleeding time; increased blood glucose; increased muscle tension or greater resistance to passive movement (hypertonia); tingling or numbness of the hands or feet; heart attack; inflammation of blood vessels; inflammation of the liver or pancreas; inflammation of the stomach wall; gum thickening; elevated liver enzymes; yellowing of the skin and eyes; increased sensitivity of the skin to light; allergic reactions, itching, rash, inflammation of the face, mouth, and/or larynx (vocal cords), along with itching and rash, severe skin reactions, including intense skin rash, urticaria, redness of the skin all over the body, severe itching, blisters, peeling, and skin inflammation, inflammation of the mucous membranes (Stevens-Johnson syndrome, toxic epidermal necrolysis) sometimes very severe.
Unknown frequency(cannot be estimated from the available data):
Tremors, rigid posture, mask-like face, slow movements, and unsteady gait.
Reporting of adverse effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date that appears on the packaging and the blister pack after CAD. The expiration date is the last day of the month indicated.
This medicine does not require special storage conditions.
Medicines should not be thrown away through the sewers or in the trash. Deposit the packaging and medicines that you no longer need in the SIGRE Point of the pharmacy. In case of doubt, ask your pharmacist how to dispose of the packaging and medicines that you no longer need. This way, you will help protect the environment.
Composition of olmesartan/amlodipine cinfa
Each tablet contains 20 mg of olmesartan medoxomil and 5 mg of amlodipine (as besylate).
Core of the tablet:pregelatinized cornstarch, microcrystalline cellulose, sodium croscarmellose, magnesium stearate.
Coating of the tablet:Opadry Y-1-7000 (hypromellose, titanium dioxide, macrogol).
Appearance of the product and package contents
Olmesartan/amlodipine cinfa 20 mg/5 mg are film-coated tablets, white, cylindrical, scored on one side, and with the inscription “O2A” on the other side.
This medicine is available in packages of 28 film-coated tablets.
Marketing authorization holder and manufacturer
Laboratorios Cinfa, S.A.
Carretera Olaz-Chipi, 10. Polígono Industrial Areta
31620 Huarte (Navarra) - Spain
Date of the last revision of this prospectus:February 2025
Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es
You can access detailed and updated information about this medicine by scanning the QR code included in the prospectus and packaging with your mobile phone (smartphone). You can also access this information at the following internet address: https://cima.aemps.es/cima/dochtml/p/82619/P_82619.html
QR code to: https://cima.aemps.es/cima/dochtml/p/82619/P_82619.html
The average price of OLMESARTAN/AMLODIPINE CINFA 20 mg/5 mg FILM-COATED TABLETS in October, 2025 is around 10.72 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for OLMESARTAN/AMLODIPINE CINFA 20 mg/5 mg FILM-COATED TABLETS – subject to medical assessment and local rules.